Special Issue "Long Non-coding RNAs in Cancer Metastasis"
Deadline for manuscript submissions: closed (15 September 2023) | Viewed by 9828
Interests: lncRNAs; tumor microenvironment; KRAS pathway; metastasis
Interests: receptor tyrosine kinase (RTK); cell signaling; cell cycle; apoptosis; drug resistance; tumor metastasis; targeted therapy; experimental therapeutics; epigenetic regulation of gene expression; ncRNAs (miRNA and lncRNA); breast cancer; non-small lung cancer (NSCLC)
Interests: non-coding RNA; EMT; tumor metastasis
Long non-coding RNAs (lncRNAs) are classified as RNA transcripts longer than 200 nucleotides and do not encode proteins. LncRNAs exert critical functions in gene regulation by altering gene levels, mRNA alternative splicing, and transcriptional and translational regulation. LncRNAs are dysregulated in a variety of malignant tumors. Growing evidence indicates that their abnormal expression can contribute to cell proliferation/growth, influence the tumor microenvironment, shape the immune response, and modulate migration/invasion and epithelial-mesenchymal transition, which eventually promote or inhibit tumor metastasis.
This Special Issue focuses on the topic relevant to lncRNA in cancer initiation, development, and metastasis via multiple pathways using state-of-the-art methodologies. Bioinformatic analysis, clinical samples, and animal models, in particular, the PDX model or gene knock-out mouse model are appreciated. It will present an update on our knowledge of the underlying molecular features and biological mechanisms of lncRNAs, including epigenetics, chromatin modulation, in-trans or in-cis gene regulation, and antitumor immunity. We invite original contributions, as well as review articles that bring novel insights to help us better understand the fascinating world of lncRNA in cancer metastasis.
We look forward to your contributions.
Prof. Dr. Lei Shi
Prof. Dr. Bolin Liu
Dr. Xiaolong Shi
Dr. Xueli Zhang
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- RNA binding protein
- tumor metastasis
- antitumor immunity
- tumor microenvironment